Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Bioo Scientific and Texas Tech Collaborate to Suppress the Progression of HIV Using Targeted RNAi

Published: Tuesday, November 17, 2009
Last Updated: Tuesday, November 17, 2009
Bookmark and Share
Dr Premlata Shankar, Professor and Co-Director, Center of Excellence of Infectious Disease Research at Texas Tech University, who has developed RNAi-based treatment methods for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the targeted delivery of siRNA into T cells.

Dr. Shankar has already successfully used RNAi to dramatically suppress HIV infection in mice by knocking down three key genes which prevented the HIV infection from spreading.

Bioo Scientific’s T3 Technology will allow Dr Shankar to precisely target the delivery of siRNAs in vivo into T-cells, although it can be used to target any cell type. The patent pending T3 Technology functions by conjugating an RNAi agent carrier to a monoclonal antibody to produce a conjugate, which is then loaded with an RNAi agent such as siRNA or miRNA molecules. The RNAi agent loaded conjugate is administered to an animal where it binds to and is internalized by cells recognized by the monoclonal antibody. The RNAi agent is then released to reduce the expression of its intended target. T3 technology can propel the validation of animal experimentation, leading to a better understanding of cellular pathways, the identification of novel drug targets, and the ability to more efficiently deliver RNAi agents as drugs.

 “I am delighted to join forces with Bioo Scientific in the development of an advanced monoclonal antibody based technology for targeted delivery of siRNA to T cells and potentially other cell types” Dr. Shankar said.  “By combining our scientific expertise and resources, we can speed up the development of robust enabling platforms for efficient delivery to desired cells and tissues in vivo which is critical for translating siRNAs into a novel class of drugs to treat human diseases.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bioo Scientific Receives USDA Approval
Approval for using its ELISA to screen meat for ractopamine residues.
Thursday, September 03, 2015
Bioo Scientific Partners with the Icahn School of Medicine at Mount Sinai
Partnership to reduce ligation bias in next generation sequencing.
Saturday, February 14, 2015
Bioo Scientific and Icahn School of Medicine Partner
Bioo Scientific partners with the Icahn School of Medicine at Mount Sinai to reduce ligation bias in next generation sequencing.
Tuesday, February 10, 2015
Bioo Scientific Awarded $750,000 NSF Grant
Company awarded a National Science Foundation Phase II grant to continue development efforts to improve the accuracy of small RNA expression analysis.
Wednesday, November 26, 2014
Bioo Scientific Receives Presidential Award for Exports
Awards are the highest recognition any U.S. entity may receive for making a significant contribution to the expansion of U.S. exports.
Thursday, May 29, 2014
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
The funding allows Bioo Scientific to develop a quantitative technology to measure miRNA expression in living cells or tumor tissue.
Wednesday, December 08, 2010
Bioo Scientific Awarded Funding from NSF for the Biomolecular Detection of miRNA
Bioo Scientific announced today that it has been awarded a grant of $150,000 from the National Science Foundation to support its research for the biomolecular detection of microRNA.
Wednesday, December 08, 2010
Bioo Scientific Chooses Eureka Genomics as its Next-Generation Sequencing Provider
Bioo Scientific chose Eureka Genomics based on their extensive sequencing experience, quick turnaround times and strong bioinformatics support.
Thursday, August 19, 2010
NSF Funds Research Partnership Between Bioo Scientific and Mirna Therapeutics
The funding will support tumor regression and pharmacokinetic studies on targeted delivery of microRNAs.
Thursday, July 22, 2010
Small RNA Barcoding for Sample Multiplexing
AIR Barcoded Adapters, designed to work with Illumina Next-Generation Sequencers, provide flexibility in high-throughput sequencing applications.
Monday, January 25, 2010
Bioo Scientific Launches a New Division, Bioo Therapeutics
Bioo Therapeutics will leverage Bioo Scientific’s proprietary drug delivery vehicles and antibody research expertise to develop therapeutic agents.
Thursday, November 12, 2009
Bioo Scientific Awarded SBIR Grant for Development of Targeted RNAi In Vivo Delivery Technology
A $500,000 Phase II grant will help to develop kits and reagents based on the patent-pending Targeted Transport Technology.
Wednesday, July 29, 2009
Bioo Scientific Corp. Receives NIH Grant for the Development of Novel Anti-Viral Therapeutics
Researchers discover a mechanism by which several viruses suppress aspects of the cell to stabilize their nucleic acids to promote an efficient infection.
Tuesday, May 05, 2009
BIOO Scientific Corp. Receives Two Grants from US Agencies
Company receives NIH grant for improving antibody technology and launches a set of novel products for directed in vivo delivery of SiRNA.
Friday, January 04, 2008
Custom RNA Interference Service
BIOO Scientific is launching a service to perform in vivo RNAi testing to facilitate progress in the drug pipeline.
Thursday, April 12, 2007
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos